These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25912930)

  • 1. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
    Schneider V; Zhang L; Rojewski M; Fekete N; Schrezenmeier H; Erle A; Bullinger L; Hofmann S; Götz M; Döhner K; Ihme S; Döhner H; Buske C; Feuring-Buske M; Greiner J
    Int J Cancer; 2015 Nov; 137(9):2083-92. PubMed ID: 25912930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
    Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
    Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
    Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
    Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
    Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ
    Transplantation; 2003 May; 75(9):1429-36. PubMed ID: 12792492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).
    Mitchell K; Steidl U
    Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31451539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
    J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
    Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
    Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
    Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
    Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Li L; Schmitt A; Reinhardt P; Greiner J; Ringhoffer M; Vaida B; Bommer M; Vollmer M; Wiesneth M; Döhner H; Schmitt M
    Cancer Immun; 2003 Jul; 3():8. PubMed ID: 12862419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.
    Zhou B; Jin X; Jin W; Huang X; Wu Y; Li H; Zhu W; Qin X; Ye H; Gao S
    J Transl Med; 2020 Jun; 18(1):254. PubMed ID: 32580769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
    Kikushige Y; Akashi K
    Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
    Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
    Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
    Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
    Ho TC; LaMere M; Stevens BM; Ashton JM; Myers JR; O'Dwyer KM; Liesveld JL; Mendler JH; Guzman M; Morrissette JD; Zhao J; Wang ES; Wetzler M; Jordan CT; Becker MW
    Blood; 2016 Sep; 128(13):1671-8. PubMed ID: 27421961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.
    Greiner J; Ringhoffer M; Taniguchi M; Li L; Schmitt A; Shiku H; Döhner H; Schmitt M
    Int J Cancer; 2004 Feb; 108(5):704-11. PubMed ID: 14696097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.